Should I buy Monster Beverage (MNST) stock or is it too late?

Monster Beverage · Consumer Staples · price $47
Logo Monster BeverageSee the full Monster Beverage (MNST) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Stifel73% of its targets hit on this sector (197 calls tested). It aims for $52.50 (+12 %), call made on July 17, 2026, maturing on July 17, 2027 (42 d ago).

The 10 reliable analysts $52+11 %
The 3 other firms $45-3.6 %
How to read it: the 10 reliable firms are not filtered by optimism — 10 aim above the price, 0 below, hence their $52 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Monster Beverage

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
RBC Capital67 %+27.3 %12$50 +7%
Stifel80 %+24.9 %25$53 +12%
Deutsche Bank86 %+23.3 %14$49 +5%
JP Morgan83 %+21.0 %6$42 -11%
Wells Fargo84 %+19.0 %19$53 +12%
BMO Capital71 %+17.8 %7$48 +2%
Morgan Stanley76 %+17.2 %25$52 +10%
Citigroup67 %+11.0 %18$57 +21%
In short — Should you invest in Monster Beverage? Is it too late, still worth it? Analysts are fairly positive (62% buy, median target $51, i.e. +8%), and the most reliable on MNST targets even higher. But the valuation is stretched (P/E ~43), it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 62% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
  • Median price target $51, i.e. +8% from the current price ($47).
  • The most reliable firm on MNST, Deutsche Bank (86% hit rate, 14 scored calls), targets $49 (call made on July 20, 2026, maturing on July 20, 2027) (+5%) in its most recent call, and $45 (call made on March 30, 2026, maturing on March 30, 2027) (-4%) in the one coming due soonest.
  • 6 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.

⚠️ Reasons to hesitate

  • The consensus is not unanimous: of 13 ratings, 5 are neutral.
  • High valuation (P/E ~43): strong growth is already "priced in", leaving little room for error.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • No dividend: your return depends only on price appreciation.

The analyst consensus on MNST

Median target $51 (+8%) · 13 ratings · Buy consensus

Strong Buy00%
Buy862%
Hold538%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Monster Beverage now?

We won't decide for you. The facts: 62% of analysts rate it a buy, median target $51 (+8%), and Deutsche Bank (most reliable on MNST, 86%) targets $49. Weigh that against valuation (P/E ~43). This is not personalized advice.

Is it too late to invest in Monster Beverage?

Not according to analysts: the median target ($51) is still +8% above the current price ($47) (most reliable on MNST: Deutsche Bank, 86%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Monster Beverage still worth investing in?

It depends on the gap between the price ($47) and its estimated value: analysts target $51 on median (+8%), with 62% buys (most reliable on MNST: Deutsche Bank, 86%). Cross-check with their real reliability on MNST and the cautions above. Information, not advice.

What's the main risk in buying MNST?

The consensus is not unanimous: of 13 ratings, 5 are neutral.

→ Go deeper: the full Monster Beverage profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)